- Home
- ADXN vs SILO Comparison
ADXN vs SILO Comparison
Compare ADXN & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | SILO |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 4.6M |
| IPO Year | 2019 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ADXN | SILO |
|---|---|---|
| Price | $5.90 | $0.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.1K | ★ 414.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,102.00 |
| Revenue This Year | $86.57 | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.29 | $0.22 |
| 52 Week High | $12.05 | $1.42 |
Technical Indicators
Market Signals| Indicator | ADXN | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 30.60 | 48.51 |
| Support Level | N/A | $0.33 |
| Resistance Level | $8.29 | $0.47 |
| Average True Range (ATR) | 0.30 | 0.03 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 2.86 | 45.70 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.